Description: Bolus infusion scheme for the adjustment of steady state [11C]Flumazenil levels in the grey matter and in the blood plasma for neuroreceptor imaging

This title appears in the Scientific Report : 2020

Bolus infusion scheme for the adjustment of steady state [11C]Flumazenil levels in the grey matter and in the blood plasma for neuroreceptor imaging

The use of hybrid PET/MR imaging facilitates the simultaneous investigation of challenge-related changes in ligand binding to neuroreceptors using PET, while concurrently measuring neuroactivation or blood flow with MRI. Having attained a steady state of the PET radiotracer using a bolus-infusion pr...

Personal Name(s):	Mauler, Jörg (Corresponding author)
	Heinzel, Alexander / Matusch, Andreas / Herzog, Hans / Neuner, Irene / Scheins, Jürgen / Wyss, Christine / Dammers, Jürgen / Lang, Markus / Ermert, Johannes / Neumaier, Bernd / Langen, Karl-Josef / Shah, N. Jon
Contributing Institute:	Physik der Medizinischen Bildgebung; INM-4 Molekulare Organisation des Gehirns; INM-2 Nuklearchemie; INM-5 Jülich-Aachen Research Alliance - Translational Brain Medicine; JARA-BRAIN Jara-Institut Quantum Information; INM-11
Published in:	NeuroImage, 221 (2020) S. 117160 -
Imprint:	Orlando, Fla. Academic Press 2020
PubMed ID:	32679251
DOI:	10.1016/j.neuroimage.2020.117160
Document Type:	Journal Article
Research Program:	Neuroimaging
Link:	Get full text OpenAccess Get full text
	Publikationsportal JuSER

Please use the identifier: http://hdl.handle.net/2128/25422 in citations.
Please use the identifier: http://dx.doi.org/10.1016/j.neuroimage.2020.117160 in citations.

The use of hybrid PET/MR imaging facilitates the simultaneous investigation of challenge-related changes in ligand binding to neuroreceptors using PET, while concurrently measuring neuroactivation or blood flow with MRI. Having attained a steady state of the PET radiotracer using a bolus-infusion protocol, it is possible to observe alterations in ligand neuroreceptor binding through changes in distribution volumes. Here, we present an iterative procedure for establishing an administration scheme to obtain steady state [11C]flumazenil concentrations in grey matter in the human brain. In order to achieve a steady state in the shortest possible time, the bolus infusion ratio from a previous examination was adapted to fit the subsequent examination. 17 male volunteers were included in the study. Boli and infusions with different weightings were given to the subjects and were characterised by values from 74 min down to 42 min. Metabolite analysis was used to ascertain the value of unmetabolised flumazenil in the plasma, and PET imaging was used to assess its binding in the grey matter. The flumazenil time-activity curves (TACs) in the brain were decomposed into activity contributions from pure grey and white matter and analysed for 12 vol of interest (VOIs). The curves highlighted a large variability in metabolic rates between the subjects, with = 54.3 min being a reliable value to provide flumazenil equilibrium conditions in the majority of the VOIs and cases. The distribution volume of flumazenil in all 12 VOIs was determined.